Program
GENSCI098
A development code. Also written as “GenSci098”.
Its studies are mostly in Graves Disease · Graves Ophthalmopathy, led by Changchun GeneScience Pharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Changchun GeneScience Pharmaceutical | 22 open or running | phase 1since Aug 14, 2024 | Aug 14, 2024 | Sep 2, 2027phase 1 · NCT06569758 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 14, 2024First study: phase 1 study in Graves OphthalmopathyFirst studyNCT06569758 · 76 planned · China
- Dec 3, 2025Phase 1 study in Graves DiseaseNCT07286656 · 24 planned · China
Ahead
- Sep 2, 2027Primary completion: phase 1 study in Graves OphthalmopathyNCT06569758
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07286656Graves Disease · China | 1 | Recruiting | Oct 28, 2026 | 24 |
| NCT06569758Graves Ophthalmopathy · China | 1 | Recruiting | Sep 2, 2027 | 76 |
How it is read
Names in the registry
- “GenSci098”, 2 entries
Codes read as this program: GENSCI098.
Conditions, from the studies’ own filings
- Graves Disease, 1 study
- Graves Ophthalmopathy, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.